Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Mar 16;10(6):e019415.
doi: 10.1161/JAHA.120.019415. Epub 2021 Mar 4.

Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25-Year Nationwide Cohorts

Affiliations
Multicenter Study

Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25-Year Nationwide Cohorts

Hanna-Kaisa Nordenswan et al. J Am Heart Assoc. .

Abstract

Background Cardiac sarcoidosis (CS) and giant cell myocarditis (GCM) share many histopathologic and clinical features. Whether they are parts of a one-disease continuum has been discussed. Methods and Results We compared medical record data of 351 CS and 28 GCM cases diagnosed in Finland since the late 1980s and followed until February 2018 for a composite end point of cardiac death, aborted sudden death, and heart transplantation. Heart failure was the presenting manifestation in 50% versus 15% (P<0.001), and high-grade atrioventricular block in 21% versus 43% (P=0.044), of GCM and CS, respectively. At presentation, left ventricular ejection fraction was ≤50% in 81% of cases of GCM versus in 48% of CS (P=0.004). The median (interquartile range) of plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) was 5273 (2782-11309) ng/L on admission in GCM versus 859 (290-1950) ng/L in CS (P<0.001), and cardiac troponin T exceeded 50 ng/L in 17 of 19 cases of GCM versus in 48 of 239 cases of CS (P<0.001). The 5-year estimate of event-free survival was 77% (95% CI, 72%-82%) in CS versus 27% (95% CI, 10%-45%) in GCM (P<0.001). By Cox regression analysis, GCM predicted cardiac events with a hazard ratio of 5.16 (95% CI, 2.82-9.45), which, however, decreased to 1.58 (95% CI, 0.71-3.52) after inclusion of markers of myocardial injury and dysfunction in the model. Conclusions GCM differs from CS in presenting with more extensive myocardial injury and having worse long-term outcome. Yet the key determinant of prognosis appears to be the extent of myocardial injury rather than the histopathologic diagnosis.

Keywords: cardiac sarcoidosis; giant cell myocarditis; inflammatory heart disease.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1. Kaplan–Meier graphs for cardiac survival free of transplantation and aborted sudden cardiac death in patients with lifetime presentation of cardiac sarcoidosis (CS) or giant cell myocarditis (GCM).
Cases with sudden death as the only disease manifestation (n=43) were excluded from the analysis.

Comment in

Similar articles

Cited by

References

    1. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2013;18:733–746. DOI: 10.1007/s10741-012-9358-3. - DOI - PubMed
    1. Litovsky SH, Burke AP, Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol. 1996;9:1126–1134. - PubMed
    1. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E, Conte JV, Tomaselli G, Garcia JGN, Hare JM. Gene expression in giant cell myocarditis: altered expression of immune response genes. Int J Cardiol. 2005;102:333–340. DOI: 10.1016/j.ijcard.2005.03.075. - DOI - PubMed
    1. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller‐Quernheim J. Sarcoidosis. Lancet. 2014;383:1155–1167. DOI: 10.1016/S0140-6736(13)60680-7. - DOI - PubMed
    1. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant‐cell myocarditis—natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336:1860–1866. - PubMed

Publication types

MeSH terms